Abstract: The present disclosure relates to a carrier for sustained-release of a drug and use thereof. The carrier is used to carry a drug. The carrier is in a gel state, a semi-solid state, or a solid state. The carrier includes a polyol fatty acid ester as a main component and a hydrogenated vegetable oil dissolved in the polyol fatty acid ester. The state of the sustained-release carrier can be adjusted by adjusting the amount of the dissolved hydrogenated vegetable oil.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: A method includes performing a first read operation on a memory cell of a programmed first one-time programmable (OTP) anti-fuse to determine a state of the memory cell based on a first parameter level, performing a second read operation on the memory cell of the programmed first OTP anti-fuse to determine the state of the memory cell based on a second parameter level, identifying the memory cell of the first OTP anti-fuse as an uncertain bit when the state determined during the first read operation and the state determined during the second read operation are different, and programing one or more memory cells of a second OTP anti-fuse based on a bit position of the identified uncertain bit of the first OTP anti-fuse.

Abstract: A memory storage device is disclosed herein which having volatile memory cells and non-volatile memory cells. The memory storage device can be implemented within a portable electronic device. These portable electronic devices often load data from non-volatile memory cells into volatile memory cells, for example, upon powering up. Conventionally, portable electronic devices often include separate non-volatile memory storage devices and volatile memory storage devices which requires a significant amount of time to transfer data stored in non-volatile memory storage devices to the volatile memory storage devices. However, the memory storage device integrates the volatile memory cells and the non-volatile memory cells into a single integrated memory device.

Abstract: A reactor, which includes a reactor body and two reactor ends sealing the ends of the reactor body, a plurality of reactor tubes extending inside the reactor body at least partially between the reactor ends, and at least one heat pipe disposed inside at least one of the reactor tubes.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: A reactor, which includes a reactor body and two reactor ends sealing the ends of the reactor body, a plurality of reactor tubes extending inside the reactor body at least partially between the reactor ends, and at least one heat pipe disposed inside at least one of the reactor tubes.

Abstract: System and method for location aware fine-grained multi-channel synchronization of mobile repositories along with aggregate analytic computation is disclosed. The System is able to improve upon existing systems by allowing for custom policies on synchronization to be stored and applied when data synchronization happens, these policies are persisted in the Sync Data Repository and applied during sync. The System is able to improve upon existing systems by allowing for persistent marking of states of the sync repository as Sync Points. This way data can be pulled from a sync point. The System is able to improve upon existing systems by having a computation framework that is able to push down aggregate analytics to user, these analytics are computed by analyzing data in the Sync Channel along various dimensions such as temporal, geo.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: System and method for location aware fine-grained multi-channel synchronization of mobile repositories along with aggregate analytic computation is disclosed. The System is able to improve upon existing systems by allowing for custom policies on synchronization to be stored and applied when data synchronization happens, these policies are persisted in the Sync Data Repository and applied during sync. The System is able to improve upon existing systems by allowing for persistent marking of states of the sync repository as Sync Points. This way data can be pulled from a sync point. The System is able to improve upon existing systems by having a computation framework that is able to push down aggregate analytics to user, these analytics are computed by analyzing data in the Sync Channel along various dimensions such as temporal, geo.